02157 LEPU BIO-B
- 4.950
- -0.320-6.07%
LEPU BIO-B News
Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5%
Lepu Biopharma (HKG:2157) will issue about 51.2 million H-shares to at least six placees for net proceeds of approximately HK$229.8 million, according to a Friday listing on the Hong Kong bourse. The
Lepu Bio-B (02157.HK) plans to place up to 51.17 million shares to raise a total of HK$234 million
Gelonghui, May 17, 丨 Lepu Bio-B (02157.HK) announced that on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, the placement agent conditionally agreed to act as the company's agent to place up to 51.17 million shares at the placement price of HK$4.58 per H share. Placed shares accounted for about 3.19% and 3.08% of the company's total issued H shares and all existing issued share capital as at the date of this announcement; they also each accounted for the company's financial allocations
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
樂普生物-B：2023年度報告
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 7% to complete clinical trial of a drug to treat advanced solid tumors
Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
Hong Kong stock changes丨Lepu Biotech surged 13%, completed clinical trials of new drugs for the first time
Glonghui, April 15 | Lepu Bio-B (2157.HK) once again increased by more than 13%, rising more than 30% on the 6th. It now reports HK$4.33, hitting a new high of more than 3 months, with a market value of HK$7.2 billion. The company recently announced that Kym, a joint venture with Conoa-B, has signed a license agreement with AstraZeneca to develop and commercialize CMG901. Currently, AstraZeneca has carried out a number of clinical studies on CMG901 treatment for advanced solid tumors. Among them, one is an advanced or metastatic gastric and gastroesophageal junction gland that expresses Claudin 18.2
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Lepu Bio-B (02157.HK) In-depth Research Report: ADC pipelines are rich in IO+ADC leading layout
Lepu Biotech is an innovative biopharmaceutical company focusing on the field of cancer treatment, especially targeted therapy and immunotherapy. The company is committed to developing innovative ADCs through an advanced ADC technology development platform, and has already listed PD-1 with the company
Changes in Hong Kong stocks 丨 Lepu Biotech surged more than 13%, and revenue surged 1347.2% in 2023
Glonghui, April 2 | Lepu Bio-B (2157.HK) rose intraday today, at one point rising by more than 13% to HK$3.61. According to the news, the company announced results on March 27, showing that revenue in 2023 increased from about RMB 16 million in the previous year to about RMB 225 million, an increase of about 1347.2%; the company's losses to its mother fell sharply by about 96.8%, from about RMB 689 million in the previous year to about RMB 122 million in the same year. According to reports, Lepu Bio-B achieved breakthrough revenue during the reporting period. Group BD revenue and subsequent technology
Lepu Bio-B (02157.HK) announced annual results and achieved a breakthrough revenue loss reduction of about 96.8%
Glonghui, March 28 | Lepu Bio-B (02157.HK) announced the results for the year ended December 31, 2023. The company's revenue increased from approximately RMB 16 million in the previous year to approximately RMB 225 million, an increase of approximately 1347.2%. The company's losses to its parent fell sharply by about 96.8%, from approximately RMB 689 million in the previous year to approximately RMB 122 million in the same year. During the reporting period, the company recorded breakthrough revenue and made significant progress in the product pipeline and business operations. The Group's BD revenue and subsequent technical service revenue is approximately RMB 1.24
Breakthrough in business development and commercialization, Lepu Bio-B (02157)'s revenue in 2023 soared 1347% to 225 million yuan
Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 2.25 during the reporting period...
LEPU BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Lepu Bio-B (02157.HK) held a board meeting on March 27 to consider and approve annual results
Glonghui March 15 | Lepu Bio-B (02157.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and deal with other matters.
LEPU BIO-B: NOTICE OF BOARD MEETING
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 13% at the end of the session, and a candidate drug candidate for pancreatic cancer was granted fast track status by the US
Lepu Bio-B (02157) rose more than 13% at the end of the session. As of press release, it was up 9.09% to HK$3.6, with a turnover of HK$10.4921 million.
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation
The US Food and Drug Administration granted Lepu Biopharma (HKG:2157) fast-track status for its MRG004A pancreatic cancer treatment, according to a Monday filing with the Hong Kong bourse. The designa
Lepu Bio-B (02157): MRG004A for the treatment of pancreatic cancer was granted fast-track status by the FDA
Lepu Bio-B (02157) announced that the company's drug candidate MRG004A (a novel targeted tissue factor...
Analysis
Price Target
No Data
